Detalimogene shows 71% CR rate in LEGEND pivotal cohort; well-tolerated in BCG-unresponsive NMIBC

enGene Therapeutics Inc.

71% complete response rate at any time (15/21 pts); 67% at 3 months; 47% at 6 months (8/17) in BCG-unresponsive NMIBC with Cis.
No drug-related discontinuations; TRAEs mostly Grade 1/2; two Grade 3 (peripheral edema, urosepsis); no Grade 4/5.
Median age 74; median 11 prior BCG doses; tumor stages: T1+Cis (14.3%), Ta+Cis (14.3%), Cis only (71.4%).
Company plans protocol refinements; conference call at 8:00 AM ET on Sept 26.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.